Mandibular Osteoradionecrosis, Bleomycin, and a Cochlear Implant
A 62-year-old woman with a history of Hodgkin lymphoma treated with mantle radiation 20 years ago develops mandibular osteoradionecrosis after a tooth extraction. She is referred for 30 hyperbaric sessions at 2.4 ATA. Her history includes bleomycin chemotherapy, a baseline DLCO of 55% predicted, resting SpO2 94% on room air, and a unilateral cochlear implant. She has no active infection, but the oral surgeon wants to place a dental implant. The chamber is multiplace and can provide air breaks. She asks whether the treatment is worth the risk and whether her implant is safe.
1. How does her pulmonary history affect the risk-benefit assessment and the HBO protocol?
Read the worked answer
Bleomycin and a DLCO of 55% predicted raise concern for oxygen toxicity and pulmonary decompensation, but they are not absolute contraindications. Risk is dose- and pressure-dependent. Reasonable modifications include lowering treatment pressure (for example, 2.0 ATA instead of 2.4 ATA if acceptable for osteoradionecrosis), using air breaks every 20–30 minutes, limiting inspired oxygen exposure, and monitoring SpO2, symptoms, and chest exam. Obtain baseline chest imaging and consider pulmonary consultation. The benefit for mandibular osteoradionecrosis is plausible but not guaranteed; staging and the surgical plan matter. The judgment is to proceed cautiously only if the expected benefit-avoiding jaw resection-outweighs a small but real risk of pulmonary injury, and to stop for chest pain, cough, or desaturation.
2. Is her cochlear implant a barrier to multiplace chamber treatment? What checks and precautions are needed?
Read the worked answer
Usually not, but it requires verification. The device is a pressure-containing implant with a small gas space; the implant model and manufacturer data matter. Check the manufacturer's maximum pressure rating and hyperbaric guidance, obtain the implant identification card, and inspect the site. In a multiplace chamber the patient can be observed directly; instruct her to report ear pain, popping, or device symptoms. Avoid direct pressure on the implant and do not take an external processor into the chamber unless it is approved for the pressure. If the device is not rated for 2.4 ATA, lower the pressure or defer. The judgment is device-specific risk management, not a blanket 'implant means no HBO.'
3. What would you recommend to the patient and surgeon about proceeding?
Read the worked answer
Recommend a shared decision with a modified protocol rather than automatic refusal or routine 2.4 ATA. Explain that HBO may improve osteoradionecrosis healing but the evidence is modest, and her reduced lung reserve makes toxicity more likely. Offer 2.0 ATA with air breaks, baseline pulmonary function tests and chest imaging, and clear stop rules; coordinate with the oral surgeon about implant timing and antibiotics. If she declines or pulmonary risk is judged too high, alternatives include surgical debridement, antibiotics, and vascularized flap reconstruction without HBO. Document the discussion. The key is that the right answer depends on osteoradionecrosis stage, surgical alternatives, and her values-not just the referral.